Generics overtake new drugs in EU centralised procedure
This article was originally published in Scrip
Executive Summary
One of the most striking statistics in the European Medicines Agency's first monthly report on the centralised approvals procedure is that generics have for the first time overtaken new products in terms of the number of applications for marketing authorisations dealt with by the agency. The report also reveals a sharp increase in the EMA's overall evaluation workload.